Blocking fgf2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings

Página do item simplificado
dc.contributor.authorde Aguiar, Rodrigo Barbosa [UNIFESP]
dc.contributor.authorParise, Carolina Bellini [UNIFESP]
dc.contributor.authorTeixeira Souza, Carolina Rosal
dc.contributor.authorBraggion, Camila [UNIFESP]
dc.contributor.authorQuintilio, Wagner
dc.contributor.authorMoro, Ana Maria
dc.contributor.authorNavarro Marques, Fabio Luiz
dc.contributor.authorBuchpiguel, Carlos Alberto
dc.contributor.authorChammas, Roger
dc.contributor.authorde Moraes, Jane Zveiter [UNIFESP]
dc.date.accessioned2019-01-21T10:30:08Z
dc.date.available2019-01-21T10:30:08Z
dc.date.issued2016
dc.description.abstractCompelling evidence suggests that fibroblast growth factor 2 (FGF2), overexpressed in melanomas, plays an important role in tumor growth, angiogenesis and metastasis. In this study, we evaluated the therapeutic use of a new anti-FGF2 monoclonal antibody (mAb), 3F12E7, using for that the B16-F10 melanoma model. The FGF2 neutralizing effect of this antibody was certified by in vitro assays, which allowed the further track of its possible in vivo application. 3F12E7 mAb could be retained in B16-F10 tumors, as shown by antibody low-pH elution and nuclear medicine studies, and also led to reduction in number and size of metastatic foci in lungs, when treatment starts one day after intravenous injection of B16-F10 cells. Such data were accompanied by decreased CD34(+) tumor vascular density and impaired subcutaneous tumor outgrowth. Treatments starting one week after melanoma cell intravenous injection did not reduce tumor burden, remaining the therapeutic effectiveness restricted to early-adopted regimens. Altogether, the presented anti-FGF2 3F12E7 mAb stands as a promising agent to treat metastatic melanoma tumors in adjuvant settings. (C) 2015 Elsevier Ireland Ltd. All rights reserved.en
dc.description.affiliationDepartamento de Radiologia e Oncologia, Faculdade de Medicina, Universidade de São Paulo, Avenida Dr Arnaldo 251, 01246-000 São Paulo, SP, Brazil
dc.description.affiliationDepartamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu 862, 04023-062 São Paulo, SP, Brazil
dc.description.affiliationLaboratório de Biofármacos em Células Animais, Instituto Butantan, Avenida Vital Brasil 1500, 05503-900 São Paulo, SP, Brazil
dc.description.affiliationCentro de Medicina Nuclear, Faculdade de Medicina, Universidade de São Paulo, Trav. Rua Dr. Ovídio Pires de Campos s/n, 05403-010 São Paulo, SP, Brazil
dc.description.affiliationUnifespDepartamento de Biofísica, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu 862, 04023-062 São Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFAPESP [98/14247-6, 09/18631-1, 13/06120-8]
dc.description.sponsorshipCAPES
dc.description.sponsorshipCNPq [11934/2013-7]
dc.description.sponsorshipCAPES-UDELAR research grants
dc.description.sponsorshipIDFAPESP: 98/14247-6
dc.description.sponsorshipIDFAPESP: 09/18631-1
dc.description.sponsorshipIDFAPESP: 13/06120-8
dc.description.sponsorshipIDCAPES: RBA
dc.description.sponsorshipIDcapes: CBP
dc.description.sponsorshipIDcapes: CB
dc.description.sponsorshipIDCNPq: CRTS
dc.description.sponsorshipIDCNPq: AMM, 11934/2013-7
dc.format.extent151-160
dc.identifierhttps://doi.org/10.1016/j.canlet.2015.11.030
dc.identifier.citationCancer Letters. Clare, v. 371, n. 2, p. 151-160, 2016.
dc.identifier.doi10.1016/j.canlet.2015.11.030
dc.identifier.issn0304-3835
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/49604
dc.identifier.wosWOS:000370457300002
dc.language.isoeng
dc.publisherElsevier ireland ltd
dc.relation.ispartofCancer Letters
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectFgf2en
dc.subjectMelanomaen
dc.subjectMonoclonal Antibodyen
dc.subjectAngiogenesisen
dc.subjectMetastasisEndothelial Growth-Factoren
dc.subjectHuman-Malignant Melanomaen
dc.subjectTumor-Growthen
dc.subjectAntigen Ceaen
dc.subjectIn-Vivoen
dc.subjectBevacizumaben
dc.subjectCellsen
dc.subjectProgressionen
dc.subjectExpressionen
dc.subjectTherapyen
dc.titleBlocking fgf2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settingsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos